1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Stockwatch: Which way is up?

 
• By Andy Smith

As the third quarter earnings season starts to trail off, investors could be forgiven for wondering what it takes anymore for the share prices of companies to go up, rather than down. Over the past two weeks, the delineation between big pharmaceutical companies and big biotechnology companies couldn't have been clearer with big biotechs like Amgen, Gilead, Celgene and Biogen reporting better than expected quarterly profits and raising guidance, whereas big pharmas like Pfizer, Lilly, GlaxoSmithKline and Bristol Myers Squibb all drifted in the shadow of their respective patent expiries (scripintelligence.com, 25 October 2012).

As the third quarter earnings season starts to trail off, investors could be forgiven for wondering what it takes anymore for the share prices of companies to go up, rather than down. Over the past two weeks, the delineation between big pharmaceutical companies and big biotechnology companies couldn't have been clearer with big biotechs like Amgen, Gilead, Celgene and Biogen reporting better than expected quarterly profits and raising guidance, whereas big pharmas like Pfizer, Lilly, GlaxoSmithKline and Bristol Myers Squibb all drifted in the shadow of their respective patent expiries (scripintelligence.com, 25 October 2012).

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

CSPC’s Global-First Monospecific ADC Promising In Advanced NSCLC

 
• By Xu Hu

CSPC’s SYS6010, the first monospecific EGFR-targeting antibody-drug conjugate in the clinic for advanced NSCLC, has shown Phase I promise, but could face close competition with another China-originated bispecific.

AstraZeneca’s Truqap Trips Up In Prostate Cancer Study

 
• By Kevin Grogan

The AKT inhibitor proves ineffective for metastatic castration-resistant disease in a Phase III trial.

J&J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With TAR-200

 
• By Alaric DeArment

The drug maker presented data from two cohorts of a pivotal Phase IIb study in NMIBC. Cost and ease of administration offer the potential to benefit the drug commercially.

Merck Set To Add Perioperative Head-And-Neck Cancer To Keytruda Label

 
• By Joseph Haas

With positive data versus radiation therapy in KEYNOTE-689, Merck & Co. files for approval in perioperative head and neck cancer, adding to additional claim in that cancer type.

More from Therapeutic Category

In Brief: Ferrer Signs Deal For Prilenia’s Pridopidine In Europe

 
• By Sushmita Panda

The companies will co-develop the drug for additional indications beyond Huntington’s disease, while Prilenia retains rights in key global markets.

EU Approves Tremfya In Third Indication, Ulcerative Colitis

 
• By Sushmita Panda

J&J secures EU approval for its IL-23 inhibitor Tremfya for ulcerative colitis, its third indication in the region, amid strong competition in the sector. EU approval is also awaited for Crohn’s disease.

J&J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With TAR-200

 
• By Alaric DeArment

The drug maker presented data from two cohorts of a pivotal Phase IIb study in NMIBC. Cost and ease of administration offer the potential to benefit the drug commercially.